Accute Effect of B-Turmactive Both on Mild and Moderate Knee Pain on Healthy Volunteers

Summary

The goal of this study is to assess the short (acutte) effect of B-Turmactive (one week treatment) both on mild/moderate knee pain

Conditions

• Knee Injuries
• Inflammation Knees

Interventions

DIETARY_SUPPLEMENT

B-turmactive

The treatment consists of daily administration of B-TURMACTIVE®. Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times: V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain). V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable

DIETARY_SUPPLEMENT

Placebo

The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product. Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times: V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain). V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable

Sponsors & Collaborators

• Hospital Universitari Sant Joan de Reus

  collaborator OTHER

• University Rovira i Virgili

  collaborator OTHER

• Technological Centre of Nutrition and Health, Spain

  lead OTHER

Principal Investigators

• Rosa M Valls, PhD · University Rovira i Virgili

• Rosa Solà, MD, PhD · Hospital Universitari Sant Joan, Universitat Rovira i Virgili, CTNS

• Anna Pedret, PhD · University Rovira i Virgili

• Elisabet Llauradó, PhD · University Rovira i Virgili

• Montse Giralt, MD, PhD · University Rovira i Virgili

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

30 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2017-09-19

Primary Completion

2017-12-19

Completion

2017-12-19

Countries

• Spain

Study Locations